Literature DB >> 11286474

Differential regulation of cell proliferation and protease secretion by epidermal growth factor and amphiregulin in tumoral versus normal breast epithelial cells.

M Silvy1, C Giusti, P M Martin, Y Berthois.   

Abstract

Amphiregulin (AR) is a heparin-binding epidermal growth factor (EGF)-related peptide that seems to play an important role in mammary epithelial cell growth regulation. We have investigated the regulation of AR-gene expression and -protein secretion by EGF in normal breast epithelial cells (HMECs), as well as in the tumoral breast epithelial cell lines MCF-7 and MDA-MB231. EGF induced a dose-dependent increase of AR mRNA level in both normal and tumoral cells. Thus, 10(-8)M EGF stimulated AR expression in HMECs to 140-300% of control. A similar EGF concentration increased AR mRNA level to 550% and 980% of control in MCF-7 and MDA-MB231 cells, respectively. This was accompanied by an accumulation of AR into conditioned culture media. However, HMECs secreted in response to EGF, 5-10 fold more AR than tumour cells. Furthermore, the potential participation of AR in the regulation of the plasminogen activator (PA)/plasmin system was investigated. Whereas HMEC-proliferation was stimulated by AR, the levels of secreted urokinase-type plasminogen activator (uPA) and type-1 plasminogen activator inhibitor (PAi-1) remained unaffected. Conversely, AR failed to regulate the proliferation of tumoral cell lines but induced an accumulation of uPA and PAi-1 into culture media. This was accompanied by an increase of the number of tumoral cells that invaded matrigel in vitro. Moreover, the presence of a neutralizing anti-uPA receptor antibody reversed the increased invasiveness of MDA-MB231 cells induced by AR. These data reveal differential behaviour of normal versus tumoral breast epithelial cells in regard to the action of AR and demonstrate that, in a number of cases, AR might play a significant role in tumour progression through the regulation of the PA/plasmin system. Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11286474      PMCID: PMC2363843          DOI: 10.1054/bjoc.2000.1678

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  32 in total

1.  Antisense expression for amphiregulin suppresses tumorigenicity of a transformed human breast epithelial cell line.

Authors:  L Ma; C Gauvillé; Y Berthois; G Millot; G R Johnson; F Calvo
Journal:  Oncogene       Date:  1999-11-11       Impact factor: 9.867

2.  Differential dose-dependent effects of epidermal growth factor on gene expression in A431 cells: evidence for a signal transduction pathway that can bypass Raf-1 activation.

Authors:  M Silvy; P M Martin; N Chajry; Y Berthois
Journal:  Endocrinology       Date:  1998-05       Impact factor: 4.736

3.  EGF induces the expression of matrilysin in the human prostate adenocarcinoma cell line, LNCaP.

Authors:  P Sundareshan; R B Nagle; G T Bowden
Journal:  Prostate       Date:  1999-08-01       Impact factor: 4.104

Review 4.  The urokinase-type plasminogen activator system in cancer metastasis: a review.

Authors:  P A Andreasen; L Kjøller; L Christensen; M J Duffy
Journal:  Int J Cancer       Date:  1997-07-03       Impact factor: 7.396

5.  Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival.

Authors:  G Fontanini; M De Laurentiis; S Vignati; S Chinè; M Lucchi; V Silvestri; A Mussi; S De Placido; G Tortora; A R Bianco; W Gullick; C A Angeletti; G Bevilacqua; F Ciardiello
Journal:  Clin Cancer Res       Date:  1998-01       Impact factor: 12.531

6.  Clinicopathologic analysis of amphiregulin and heregulin immunostaining in breast neoplasia.

Authors:  D W Visscher; F H Sarkar; T C Kasunic; K B Reddy
Journal:  Breast Cancer Res Treat       Date:  1997-08       Impact factor: 4.872

7.  mRNA expression of transforming growth factor alpha in human breast carcinomas and its activity in effusions of breast cancer patients.

Authors:  F Ciardiello; N Kim; D S Liscia; C Bianco; R Lidereau; G Merlo; R Callahan; J Greiner; C Szpak; W Kidwell
Journal:  J Natl Cancer Inst       Date:  1989-08-02       Impact factor: 13.506

8.  Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells.

Authors:  E L Rosenthal; T M Johnson; E D Allen; I J Apel; A Punturieri; S J Weiss
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

9.  A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF.

Authors:  S Higashiyama; J A Abraham; J Miller; J C Fiddes; M Klagsbrun
Journal:  Science       Date:  1991-02-22       Impact factor: 47.728

10.  Amphiregulin: a bifunctional growth-modulating glycoprotein produced by the phorbol 12-myristate 13-acetate-treated human breast adenocarcinoma cell line MCF-7.

Authors:  M Shoyab; V L McDonald; J G Bradley; G J Todaro
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

View more
  8 in total

1.  Mammary tumorigenesis induced by fibroblast growth factor receptor 1 requires activation of the epidermal growth factor receptor.

Authors:  Lindsey K Bade; Jodi E Goldberg; Hazel A Dehut; Majken K Hall; Kathryn L Schwertfeger
Journal:  J Cell Sci       Date:  2011-08-24       Impact factor: 5.285

2.  Gene alteration of intestinal intraepithelial lymphocytes in response to massive small bowel resection.

Authors:  Barbara E Wildhaber; Hua Yang; Arnold G Coran; Daniel H Teitelbaum
Journal:  Pediatr Surg Int       Date:  2003-05-01       Impact factor: 1.827

Review 3.  Amphiregulin as a novel target for breast cancer therapy.

Authors:  Nicole E Willmarth; Stephen P Ethier
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-04-25       Impact factor: 2.673

4.  Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells.

Authors:  Niels Eckstein; Kati Servan; Luc Girard; Di Cai; Georg von Jonquieres; Ulrich Jaehde; Matthias U Kassack; Adi F Gazdar; John D Minna; Hans-Dieter Royer
Journal:  J Biol Chem       Date:  2007-10-17       Impact factor: 5.157

Review 5.  Amphiregulin: role in mammary gland development and breast cancer.

Authors:  Jean McBryan; Jillian Howlin; Silvia Napoletano; Finian Martin
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-04-09       Impact factor: 2.673

6.  Mesenchymal Stem Cells Shed Amphiregulin at the Surface of Lung Carcinoma Cells in a Juxtacrine Manner.

Authors:  Oriane Carnet; Julie Lecomte; Anne Masset; Irina Primac; Tania Durré; Ludovic Maertens; Benoit Detry; Silvia Blacher; Christine Gilles; Christel Péqueux; Jenny Paupert; Jean-Michel Foidart; Guy Jerusalem; Didier Cataldo; Agnès Noel
Journal:  Neoplasia       Date:  2015-07       Impact factor: 5.715

7.  Exosome-bound WD repeat protein Monad inhibits breast cancer cell invasion by degrading amphiregulin mRNA.

Authors:  Makio Saeki; Hiroshi Egusa; Yuya Kamano; Yoshito Kakihara; Walid A Houry; Hirofumi Yatani; Shinzaburo Noguchi; Yoshinori Kamisaki
Journal:  PLoS One       Date:  2013-07-03       Impact factor: 3.240

8.  Amphiregulin enhances intercellular adhesion molecule-1 expression and promotes tumor metastasis in human osteosarcoma.

Authors:  Ju-Fang Liu; Ya-Ting Tsao; Chun-Han Hou
Journal:  Oncotarget       Date:  2015-12-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.